Esther Hagai

Esther Hagai

Company: Clexio Biosciences

Job title: Chief Medical Officer


Exploring Potential Impacts of COVID on Major Depressive Disorder Trial Data 1:10 pm

The talk will present the results from CLEO phase 2 trial to assess the safety and efficacy ofbCLE-100 as an adjunctive treatment for Major Depressive Disorder (MDD) with inadequate response to previous antidepressants. • It will explore Potential Impacts of COVID-19 on Major Depressive Disorder Trial Data • CLE-100 is an oral esketamine tablet formulated…Read more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.